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As a transcription factor, MYCN regulates myriad target genes including the histone 
chaperone FACT. Moreover, FACT and MYCN expression form a forward feedback 
loop in neuroblastoma. It is unclear whether MYCN is involved in chromatin remodeling 
in neuroblastoma through regulation of its target genes. We showed here that MYCN 
knockdown resulted in loss of the nucleosome-free regions through nucleosome 
assembly in the promoters of genes functionally enriched for DNA repair. The active mark 
H3K9ac was removed or replaced by the repressive mark H3K27me3 in the promoters of 
double-strand break repair-related genes upon MYCN knockdown. Such chromatin state 
alterations occurred only in MYCN-bound promoters. Consistently, MYCN knockdown 
resulted in a marked increase in DNA damage in the treatment with hydroxyurea. In 
contrast, nucleosome reorganization and histone modification changes in the enhancers 
largely included target genes with tumorigenesis-related functions such as cell proliferation, 
cell migration, and cell–cell adhesion. The chromatin state significantly changed in both 
MYCN-bound and MYCN-unbound enhancers upon MYCN knockdown. Furthermore, 
MYCN knockdown independently regulated chromatin remodeling in the promoters and 
the enhancers. These findings reveal the novel epigenetic regulatory role of MYCN in 
chromatin remodeling and provide an alternative potential epigenetic strategy for MYCN-
driven neuroblastoma treatment.
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INTRODUCTION
Neuroblastoma is a cancer that arises in neural-crest tissues, typically in sympathetic ganglia and 
adrenal glands. It generally occurs in children under 5 years of age, with the median age at diagnosis 
of about 17 months (London et al., 2005), with an incidence of dozens of cases per million children 
(Stiller and Parkin, 1992; Maris, 2010). Neuroblastoma is the most malignant and common solid 
MYCN Regulates Chromatin Remodeling in NeuroblastomaHu et al.
2 July 2019 | Volume 10 | Article 684Frontiers in Genetics | www.frontiersin.org
tumor diagnosed in the first year of life (Maris, 2010). It accounts 
for the disproportionately high mortality among the cancers of 
childhood.
The c-MYC homolog MYCN (encoding the transcription 
factor N-MYC), a proto-oncogene, was originally isolated 
from neuroblastoma cells (Kohl et al., 1983; Schwab et al., 
1983). MYCN contains a basic helix-loop-helix (bHLH) 
domain. It binds to DNA as a dimer with another bHLH 
protein. MYCN plays critical roles in regulating many 
cellular processes such as cell growth, differentiation, and 
apoptosis. MYCN amplification is often associated with a 
variety of tumors, mostly neuroblastoma. The overexpression 
of MYCN contributes to the genesis of neuroblastoma in 
the transgenic mice (Weiss et al., 1997). It was reported that 
MYCN expression was required to activate the differentiation 
in neuroblastoma cells (Guglielmi et al., 2014). Approximately 
25% of neuroblastoma tumors harbor amplification of 
MYCN (Matthay et al., 2016) that strongly correlates with 
a poor prognosis (Janoueix-Lerosey et al., 2009). MYCN 
amplification is also often associated with genetic variations 
such as segmental chromosomal loss (Thompson et al., 2016). 
Consistently, the most malignant neuroblastoma contains 
amplification of MYCN (Matthay et al., 2016). Therefore, 
MYCN amplification is a significant predictor of poor clinical 
outcome in neuroblastoma patients.
As a transcription factor, MYCN regulates transcription 
of many genes. Based on the MYC target gene signature, 
we identified FACT (facilitates chromatin transcription), 
encoding a histone chaperone, as a therapeutic target in 
neuroblastoma (Carter et al., 2015). Human FACT consists 
of two subunits Spt16 and SSRP1 (Orphanides et al., 
1999). FACT is highly conserved in eukaryotes (Brewster 
et al., 1998). Notably, FACT as a histone chaperone plays a 
critical role in chromatin architecture through regulating 
nucleosome assembly and eviction, for example, stability of 
H2A-H2B dimer (Orphanides et al., 1998; Reinberg and Sims, 
2006; Winkler and Luger, 2011; Formosa, 2012). FACT also 
functioned in DAN repair by activating p53 and linking to 
H2AX (Heo et al., 2008). Interestingly, MYCN and FACT 
expression formed a positive feedback loop in neuroblastoma 
cells. Inhibition of MYCN down-regulated FACT expression 
in neuroblastoma cells, and vice versa (Carter et al., 2015). 
Thus, it is very likely that MYCN can also alter chromatin 
state indirectly through its target genes. However, this remains 
unexplored in neuroblastoma.
To address these questions, we knocked down MYCN in 
the human neuroblastoma cell line BE(2)C and profiled the 
transcriptome, the genome-wide nucleosome occupancy, 
and key histone modification signals. Epigenomics analyses 
revealed that MYCN knockdown altered nucleosome 
reorganization and histone modifications. The chromatin 
remodeling induced by MYCN knockdown was functionally 
enriched for cell proliferation and DNA repair, creating a 
synthetic lethal environment. These findings established a novel 
link between MYCN knockdown and chromatin remodeling 
and provided a potential therapeutic strategy for MYCN-driven 
neuroblastoma.
RESULTS
Knockdown of MYCN Down-Regulates 
FACT in Neuroblastoma Cells
To investigate how MYCN regulates chromatin state, we knocked 
down MYCN in MYCN-amplified BE(2)C neuroblastoma cells 
using small interfering RNA (siRNA). The quantitative assays 
showed the significant decrease in the expression of MYCN 
and the two FACT subunits (SPT16 and SSRP1) at both mRNA 
and protein levels (Figures 1A, B). This is consistent with our 
previous results (Carter et al., 2015). We further profiled the 
genome-wide gene expressions using RNA-seq with high 
reproducibility (Supplementary Figure 1A). The results 
confirmed the significant decrease in the expression of MYCN, 
SPT16, and SSRP1 (Supplementary Figure 1B). Furthermore, 
the previously reported 51 MYC target genes (Ji et al., 2011) 
in neuroblastoma tumors were significantly down-regulated 
as MYCN knockdown (Figures 1C, D and Supplementary 
Figure 1C). These results together demonstrated that MYCN 
knockdown was successful and consequently down-regulated 
FACT expression in neuroblastoma cells.
MYCN Knockdown Disturbs Nucleosome 
Positioning in the Promoters and Impedes 
DNA Repair
We next profiled genome-wide nucleosome occupancy to 
investigate how MYCN impacts nucleosome positioning. The 
nucleosome occupancy is highly reproducible (Supplementary 
Figure 2A). MYCN knockdown did not result in significantly 
different nucleosome occupancy on a genome scale 
(Supplementary Figure 2B). However, we observed that more 
than 98% of all nucleosomes that shifted were assembled or 
evicted in response to MYCN knockdown (Figure 2A). Our 
previous studies showed that nucleosome eviction or assembly 
in cis regulatory elements played a critical role in embryonic 
development, cell differentiation, etc. (Shi et al., 2014; Ye et al., 
2016; Du et al., 2017; Ye et al., 2017). Therefore, we examined 
nucleosome positioning dynamics in the promoters when 
MYCN was knocked down. There exists −1, nucleosome free 
regions (NFRs), +1, +2, etc. canonical nucleosome arrangement 
around transcription start site (TSS) and gene body. The NFR 
locates in the upstream 200 bp to downstream 50 bp regions of 
TSS. If an NFR in the control sample overlapped at least 80% 
of a nucleosome upon MYCN knockdown, the NFR was lost in 
the MYCN knockdown sample, and vice versa (see Materials and 
Methods for details). The results showed that MYCN knockdown 
led to nucleosome assembly in a set of promoters of the genes 
enriched in the functions of DNA repair, double-strand break 
repair via nonhomologous end join, and nervous system 
development (Figure 2B). Consistently, MYCN knockdown 
resulted in a marked increase in the DNA damage marker γH2AX 
when the cells were treated with hydroxyurea (Figures 2C, D). 
We further obtained experiment-validated MYCN binding sites 
in BE(2)C cells (Zeid et al., 2018) to check whether MYCN bound 
promoters. The results showed that 74% of 1,099 promoters have 
both NFR loss upon MYCN knockdown and MYCN binding in 
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the control sample. Taken together, this suggested that loss of 
the 5′ NFRs through nucleosome positioning in the promoters 
resulting from MYCN knockdown impeded DNA repair. In 
contrast, nucleosomes were evicted to form NFRs in another 
set of promoters that were enriched in the functions of positive 
regulation of cell proliferation, regulation of cytokinesis, B cell 
activation, and endocytosis (Supplementary Figure 2C).
MYCN Knockdown Alters Chromatin State 
in the Promoters
In addition to nucleosome occupancy, histone modifications 
in the promoters are also important to gene activity. Therefore, 
we investigated histone modification changes in the promoters 
in response to MYCN knockdown. We conducted chromatin 
immunoprecipitation followed by parallel massive sequencing 
(ChIP-seq) for the key histone modifications before and after 
MYCN knockdown with high reproducibility (Supplementary 
Figure 3A).
We first explored the changes of active H3K4me3 and 
repressive H3K27me3 that could form bivalent domains in 
the promoters and played a critical role in gene transcription 
regulation (Kouzarides, 2007). Surprisingly, chromatin states 
in the promoters defined by H3K4me3 and H3K27me3 
signals largely remained unchanged before and after MYCN 
knockdown (Supplementary Figure 3B). Our previous study 
FIGURE 1 | Knockdown of MYCN down-regulates the expression of FACT in neuroblastoma. (A) quantitative polymerase chain reaction (qPCR) results of MYCN, 
SPT16, and SSRP1. Error bars are SEM. (**p < 0.01, Student’s t test). (B) Western blots for MYCN, SPT16, and SSRP1 protein expression in BE(2)C cells 
treated with control and MYCN knockdown. (C) MYCN target genes are down-regulated in MYCN knockdown. (*p < 0.05, Student’s t test). (D) Heatmap showing 
the expression levels of the 51 MYCN target genes in BE(2)C cells treated with control and MYCN knockdown.
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found that another combination of histone modifications 
H3K9ac and H3K27me3 in the promoters were also critical to 
gene transcription regulation (Du et al., 2017). Therefore, we 
next examined the changes of H3K9ac and H3K27me3 in the 
promoters. H3K9ac signals were removed in many promoters 
(Figure 3A). Consequently, gene expression levels were 
decreased as H3K9ac signals in the promoters were removed 
or replaced by H3K27me3 (Figure 3B). H3K36me3 signals 
in the gene body changed in the same manner (Figure 3C). 
Interestingly, we performed gene ontology (GO) analysis of the 
genes with only H3K9ac in the promoters that was replaced 
by H3K27me3, H3K9ac/H3K27me3, or none after MYCN 
knockdown and identified enrichment for double-strand 
break repair (Figure 3D), suggesting that MYCN knockdown 
suppressed ribosome biogenesis, rRNA processing, rRNA 
metabolic process, and repair of DNA damage by altering 
chromatin state in the promoters. To confirm this, we obtained 
experiment-validated MYCN binding sites in BE(2)C cells 
(Zeid et al., 2018) and classified promoters into two groups: 
MYCN-bound and MYCN-unbound. Intriguingly, there was a 
significantly higher portion of MYCN-bound promoters whose 
chromatin state changed from active to non-active upon MYCN 
knockdown compared with the MYCN-unbound promoters 
(Supplementary Figure 3C). Further analysis found that 
H3K9ac signals were significantly decreased in the MYCN-
bound promoters after MYCN knockdown. In contrast, H3K9ac 
FIGURE 2 | MYCN knockdown results in nucleosome remodeling and marked increase in DNA damage. (A) Pie charts showing the portions of fixed nucleosome, 
shift, loss, and gain of nucleosome. Fixed nucleosomes share the same positions before and after MYCN knockdown. Shift nucleosomes include the nucleosome 
pairs before and after MYCN knockdown with overlapping ≥ 30 bp and <147 bp (a nucleosome length). Nucleosome loss and gain consists of the rest of 
nucleosomes. (B) Loss of the NFRs in the promoter regions of a set of genes after MYCN knockdown through nucleosome assembly (left heatmap). Significantly 
enriched GO terms for this set of genes (right bar plot). (C) Western blots for γH2AX and MYCN protein expression in BE(2)C cells treated for 24 h with or without 
hydroxyurea (HU), then for another 24 h with siRNA for MYCN knockdown after hydroxyurea withdrawal. (D) Quantitative analysis of γH2AX and MYCN protein 
expression in (C). (**p < 0.01, n.s., not significant, Student’s t test)
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signals remained unchanged in the MYCN-unbound promoters 
(Figures 3E, G and Supplementary Figures 3D, E). Of note, 
MYCN bound to the promoters of the genes (e.g., Fen1, Smc6, 
Cen1 and Rad54b) with functions of DNA damage repair. 
H3K9ac signals in their promoters were significantly reduced 
after MYCN knockdown (Figure 3F and Supplementary Figure 
3D). Taken together, MYCN binding in the promoters regulated 
translational process or transcription of rRNA genes and the 
function of DNA repair by altering chromatin state.
Histone Modification Changes in the 
Enhancers Upon MYCN Knockdown
Transcription-factor-bound enhancers play an important role in 
regulating gene expression (Bulger and Groudine, 2011). Histone 
modifications in enhancers control their activity. Therefore, we 
next investigated histone modification changes in the enhancers 
upon MYCN knockdown.
In order to identify enhancers and determine their chromatin 
state in neuroblastoma cells, we performed ChIP-seq of 
FIGURE 3 | H3K9ac signals decrease in the promoters upon MYCN knockdown. (A) The alluvial plot shows the dynamics of histone modifications (HMs) in the 
promoters upon MYCN knockdown. (B) Changes in expression levels of the genes with H3K9ac+/H3K27me3− promoters in the control. The genes are categorized 
by HMs in the promoters in the MYCN knockdown sample. Overall, loss of active H3K9ac is associated with decreased expression (***p < 0.001, n.s., not 
significant, Wilcoxon rank sum test). (C) Loss of active H3K9ac is associated with decreased H3K36me3 signals in the gene body. The gene sets are the same 
as in (B) (***p < 0.001, Wilcoxon rank sum test). (D) Functional annotation of the genes with H3K9ac+/H3K27me3− promoters that are replaced by H3K27me3+, 
H3K9ac+/H3K27me3+, or none after MYCN knockdown. (E) H3K9ac signals are significantly reduced in the MYCN-bound promoters upon MYCN knockdown 
whereas H3K9ac signals remain the similar levels in the MYCN-unbound promoters (***p < 0.001, Wilcoxon rank sum test). (F, G) Track view of MYCN binding and 
H3K9ac signals in the promoter (marked in the red box) of the representative genes Fen1 (a double-strand break repair related gene) (F) and Gprin2 (G).
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H3K4me1 and H3K27ac. The results were highly reproducible 
(Supplementary Figure 4A). Enhancers were predicted based 
on H3K4me1 signals using the tool Homer (Heinz et al., 2010). 
The chromatin state of enhancers was determined by the histone 
modifications on enhancers: active (H3K4me1+ and H3K27ac+), 
intermediate (H3K4me1+, H3K27ac+, and H3K27me3+), poised 
(H3K4me1+ and H3K27me3+), primed (H3K4me1+ only), and 
off (H3K4me1−).
Upon MYCN knockdown, most of the active, intermediate, 
and poised enhancers remained in the same chromatin state 
(Figure 4A). In contrast, the majority (63.6%) of primed 
enhancers became off enhancers, and 81.7% of off enhancers 
became primed enhancers (Supplementary Figure 4B).
To investigate the relationship between MYCN binding 
and chromatin state change in the enhancers upon MYCN 
knockdown, we used the MYCN binding sites in BE(2)C 
cells (Zeid et al., 2018) to categorize enhancers into MYCN-
bound and MYCN-unbound two groups. Surprisingly, unlike 
promoters (Figure  3E), both H3K27ac and H3K27me3 signals 
were significantly changed in both MYCN-bound and MYCN-
unbound enhancers upon MYCN knockdown (Figure 4B and 
Supplementary Figure 4C). We further did motif enrichment 
analysis in these two types of enhancers. As expected, the top 
10 enriched motifs in MYCN-bound enhancers are all E-box 
(CACGTG)-related motifs such n-Myc, MNT, Max, c-Myc, 
NPAS, BMAL1, NPAS2, CLOCK, c-Myc, and USF1. In contrast, 
the top 10 enriched motifs in MYCN-unbound enhancers include 
Gata2, Gata6, EBF1, Lhx1, Gata1, Phox2b, Gata3, Gata4, Prop1, 
and Ap-2α. This indicates that transcription factors containing 
zinc finger domain (Gata family) and homeobox (Phox2b and 
Prop1) regulate MYCN-unbound enhancers.
To understand which functions were impacted through 
chromatin state changes in enhancers upon MYCN knockdown, 
we did GO analysis of the active enhancers that changed to 
non-active enhancers upon MYCN knockdown and identified 
enrichment for cell fate determination, negative regulation 
of cell proliferation, and negative regulation of cell migration 
(Figure  4C). Nucleosome eviction and assembly in enhancers 
also played a critical role in regulating gene expression (Ye 
et  al., 2016; Ye  et  al., 2017). Therefore, we identified 3809 
enhancers with NFR loss through nucleosome assembly upon 
MYCN knockdown (Figure 4D). The GO analysis revealed that 
these enhancers were enriched for cell proliferation, negative 
regulation of cell proliferation, and cell migration (Figure 4E). 
Additionally, the breadth of H3K4me3 domains had critical roles 
in regulating gene expression (Liu et al., 2016). Thus, we identified 
the enhancers whose width became broader and that remained 
active upon MYCN knockdown. The GO analysis revealed that 
these enhancers were enriched for cell division, cell migration, 
and cell–cell adhesion (Supplementary Figure 4D). Notably, all 
these GO terms were related to cancer initiation and progression. 
Collectively, MYCN knockdown altered chromatin state in the 
enhancers in multiple manners and impacted functions related 
to tumorigenesis and cancer progression.
FIGURE 4 | Chromatin state changes in the enhancers upon MYCN knockdown. (A) The alluvial plot shows the dynamics of histone modifications (HMs) in the 
enhancers upon MYCN knockdown. (B) H3K27ac signals are significantly reduced in both MYCN-bound and MYCN-unbound enhancers upon MYCN knockdown 
(***p < 0.001, Wilcoxon rank sum test). (C) GO terms for which the enhancers are enriched whose chromatin state change from active to non-active upon MYCN 
knockdown. (D) Loss of the NFRs in the enhancers after MYCN knockdown through nucleosome assembly. (E) GO terms for which the enhancers are enriched 
whose NFRs are lost upon MYCN knockdown.
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MYCN Knockdown Independently Alters 
Chromatin State in the Promoters and the 
Enhancers
Genome-wide Hi-C study showed that chromatin loops 
mediated enhancer–promoter interactions. Our previous 
study revealed that chromatin state changes in the enhancers 
and the promoters regulated gene expression in synergy (Ye 
et al., 2017). Thus, we further investigated whether there was a 
correlation between chromatin state changes in these two type 
of cis regulatory elements upon MYCN knockdown. We first 
associated the nearest promoter within 100 kb to each enhancer. 
Next, we grouped the enhancers by chromatin change upon 
MYCN knockdown. Then, we classified the associated promoters 
by chromatin state change and counted the promoters for each 
group of enhancers. The results showed no correlation between 
chromatin state changes in the promoters and the enhancers 
(Table 1). Similarly, we grouped the promoters by chromatin 
change upon MYCN knockdown and examined chromatin 
change in the associated enhancers for each group of promoters. 
The results also showed no correlation between chromatin 
state changes in the promoters and the enhancers (Table 2). 
Collectively, these findings suggested that chromatin states in 
the promoters and the enhancers independently changed upon 
MYCN knockdown.
DISCUSSION
Chromatin structure controls the binding of myriad transcription 
factors. Aberrant chromatin structures result in a state of 
“epigenetic instability”. Accordingly, the gene expressions are 
altered and the differentiation and proliferation programs are 
perturbed. As a result, these aberrant changes of chromatin 
structures predispose to oncogenic transformation. In this study, 
the epigenomics analyses revealed that MYCN knockdown 
changed nucleosome organization and chromatin states in the 
promoters and the enhancers likely through regulating target 
genes. As a result, repair of DNA damage was impaired. These 
findings revealed MYCN’s distinct function of chromatin 
remodeling other than its roles as a classical transcription factor. 
Since MYCN is an important oncogene and its amplification is 
observed in many cancers, the role of chromatin remodeling for 
MYCN may be conserved in other cancers. This study provided 
the molecular basis for potential neuroblastoma therapy 
approach through chromatin remodeling.
MYCN, as a classical transcription factor, played a pivotal 
role in tumorigenesis and cancer progression that has been 
extensively studied. MYCN and its partner Max formed a 
heterodimer and bound to the conserved regulatory element 
E-box of the target genes to regulate their expression (Gherardi 
et al., 2013). As a result, MYCN regulated a variety of cancer-
related biological processes such as apoptosis, angiogenesis, 
invasion, and metabolism (Bell et al., 2010; Westermark et al., 
2011). For example, MYCN regulated neuroblastoma initiation 
by activating polycomb protein BMI1 (Ochiai et al., 2010) that 
decreased p53 protein stability (Calao et al., 2013). Although 
MYCN regulated some target genes through recruiting or 
interacting with chromatin remodeling complex (Cotterman 
et al., 2008; Gherardi et al., 2013), it remained elusive whether 
MYCN had a function of chromatin remodeling. This study 
demonstrated that MYCN played a role in regulating nucleosome 
positioning and histone modifications in both the proximal and 
the distal regulatory regions in neuroblastoma cells BE(2)C. 
Therefore, these findings implicated a novel epigenetic regulatory 
role of MYCN regardless of its transcription regulatory role as a 
classical transcription factor.
MYCN regulated many target genes including histone 
chaperones. For example, our previous study found that FACT was 
an MYCN target gene. Moreover, MYCN and FACT expression 
formed a positive feedback loop in neuroblastoma cells. FACT 
inhibition caused cell death in vitro by facilitating cancer cell death 
TABLE 1 | Statistics of categorized promoters associated with enhancers 
classified by chromatin state change upon MYCN knockdown.
Enhancer chrom 
state change upon 
MYCN KD
Count of the associated promoters categorized 
by chrom state change
Active → 
non-active
Non-active → 
active
p value
Off → primed 361 169 0.74
Primed → off 494 241
Non-active → active 143 80 0.68
Active → non-active 193 100
Narrow → wide 45 26 0.62
Wide → narrow 85 57
p value, chi-square test.
TABLE 2 | Statistics of categorized enhancers associated with promoters 
classified by chromatin state change upon MYCN knockdown.
Promoter chrom 
state change upon 
MYCN KD
Count of the associated enhancers categorized by 
chrom state change
Active → non-active Non-active → active p 
value
Non-active → active 246 167 0.14
Active → non-active 421 343
Promoter chrom 
state change upon 
MYCN KD
Count of the associated enhancers categorized 
by chrom state change
Primed → off Off → primed p 
value
Non-active → active 671 421 0.95
Active → non-active 1387 866
Promoter chrom 
state change upon 
MYCN KD
Count of the associated enhancers categorized by 
chrom state change
Wide → narrow Narrow → wide p 
value
Non-active → active 120 49 0.99
Active → non-active 183 75
p value, chi-square test.
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through blocking repair of DNA damage (Carter et al., 2015). 
Consistently, our results showed that MYCN knockdown down-
regulated expression of the two subunits of FACT and resulted in 
marked increase in DNA damage in neuroblastoma cells. However, 
we still lack evidence whether MYCN alters chromatin structures 
mainly through its forward feedback loop with FACT. Moreover, 
it is not fully understood how this chromatin remodeling affects 
the specific DNA repair pathways. Further in-depth studies will 
be required to address these questions.
MATERIALS AND METHODS
Cell Culture and RNAi
The human neuroblastoma cell line BE(2)C was cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Life Technologies 
11995065) supplemented with 10% FBS (fetal bovine serum) at 
37°C with 5% CO2. siRNAs used were non-targeting control 
siRNA (Qiagen 1027281) and MYCN (Qiagen SI03087518).
On the first day, cells were cultured in 60-mm dishes, ~4 × 
105 cells/dish. On the second day, 4 μl of 20 mM siRNA and 
16 μl of Lipofectamine 2000 (Life Technologies 11668019) were 
incubated with 1 ml of Optimem (Life Technologies 51985034) 
at RT (room temperature) for 5 min, respectively. Then, these 
two 1-ml volumes of Optimem were mixed and left at RT for 
20 min. DMEM was removed from the cells cultured on the first 
day. The cells were washed once with PBS (Life Technologies 
10010023). Add the above 2 ml of Optimem mixed with siRNA 
and Lipofectamine 2000 to the dish at 37°C for 6 h. Add 2 ml 
of DMEM supplemented with 20% FBS to the dish. At this 
point, there was a total of 4 ml of mixture, and the final siRNA 
concentration was 40 nM. On the third day, the cells were 
collected for later use.
mRNA Extraction and qRT-PCR
The total RNA was isolated using RNAsimple Total RNA Kit 
(TIANGEN DP419), and the RNA concentration was measured 
using NanaDrop 2000 (Thermo Scientific). The integrity of 
RNA was tested by running AGE (agarose gel electrophoresis). 
Reverse transcription of RNA utilized PrimeScript™ RT Master 
Mix (TAKARA RR036A), subsequently followed by real-time 
PCR using SYBR®Premix Ex Taq™ (TAKARA RR420A). Relative 
abundance of mRNA transcript for the selected genes was 
calculated using the ΔΔCt approximation relative to housekeeping 
gene GAPDH. The real-time PCR primers were MYCN-F 
5′-ACAGTGAGCGTCGCAGAAAC-3′, MYCN-R 5′-AGCAA 
GTCCGAGCGTGTTC-3′, GAPDH-F 5′-AATCCCATCACCA 
TCTTCC-3′, and GAPDH-R 5′-CATCACGCCACAGTTTCC-3′.
Antibodies
The antibodies used for ChIP were IgG (cell signaling 2729), 
H3K4me1 (Abcam ab8895), H3K4me3 (Abcam ab8580), H3K9ac 
(Abcam ab10812), H3K27ac (Abcam ab4729), H3K27me3 (Active 
motif 39155), and H3K36me3 (Abcam ab9050). The following 
antibodies were used for Western blot: mouse anti-SPT16 
(BioLegend 607002, 1:1000), mouse anti-SSRP1 (BioLegend 
609702, 1:500), mouse anti-MYCN (Santa Cruz Biotechnology 
Sc53993, 1:1000), mouse anti-γH2AX (Abcam ab26350, 1:1000), 
mouse anti-GAPDH (Abcam ab8245, 1:10000), and anti-mouse 
HRP (Thermo Scientific 32430, 1:1500).
Western Blotting
The total protein was isolated in RIPA lysis buffer, and protein 
concentration was measured by using Enhanced BCA Protein 
Assay Kit (Beyotime P0010S). Equivalent amounts of protein were 
separated by SDS-PAGE and blocked by standard methodologies. 
Immobilon-NC Transfer Membrane (Millipore HATF00010) was 
successively incubated with primary antibody at 4°C overnight and 
with second antibody at RT for 1 h. Enhanced chemiluminescence 
agent was SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific 34087), which was used according to the 
manufacturer’s instructions. GAPDH was used as the internal 
reference. Films were analyzed using Image J (NIH), and all samples 
were normalized to the control sample and reference gene GAPDH.
DNA Damage and Repair
On the first day, cells were cultured in 60-mm dishes, ~4 × 105 
cells/dish. Hydroxyurea (HU) (Selleck S1896) was added to 
DMEM in the dish, and the final concentration was 2 mM. On 
the second day, DMEM containing HU was removed and 2 ml of 
Optimem mixed with siRNA and Lipofectamine 2000 was added 
to the dish. Other operations were the same with RNAi.
MNase-Seq and Chip-Seq
A total of ~1 × 107 cells were cross-linked with 1% formaldehyde 
at RT for 8 min, and the cross-linking was terminated by adding 
0.125 M glycine at RT for 5 min. Cells were collected for lysis 
to isolate nuclei. Suspend the nuclei in 1 ml of MNase digestion 
buffer [10 mM Tris–HCl, pH 7.5, 15 mM NaCl, 60 mM KCl, 
1 mM CaCl2, 0.15 mM spermine, 0.5 mM spermidine, and 1× 
PI (Roche 04693132001)]. Add 3 μl of MNase (Micrococcal 
Nuclease; NEB M0247S) at 37°C for 25 min. The digestion was 
terminated by adding EDTA to a final concentration of 10 mM. 
Reverse cross-linking by adding proteinase K at 65°C for 2–4 h. 
Mononucleosomal DNA fragments were purified using phenol-
chloroform and examined by running AGE.
Approximately 15 μg of nucleosomal DNA and 3–5 μg of 
histone modification (HM) antibodies were mixed together with 
430 μl of ChIP buffer (20 mM Tris–HCl, pH 8.1, 2 mM EDTA, 
150 mM NaCl, 0.1% Triton X-100, and 1× PI) for chromatin 
immunoprecipitation. The mixture was incubated overnight 
at 4°C with rotation. Twenty-five microliters of ChIP-Grade 
Protein G Magnetic Beads (Cell Signaling 9006S) was added 
to the mixture for another 2 h rotation at 4°C. The beads were 
successively washed three times by low salt wash buffer (20 mM 
Tris–HCl, pH 8.1, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 
and 0.1% SDS), and once by high salt wash buffer (20 mM Tris–
HCl, pH 8.1, 2 mM EDTA, 500 mM NaCl, 1% Triton X-100, and 
0.1% SDS). ChIP’ed DNA fragments were eluted by ChIP elution 
buffer (50 mM Tris–HCl, pH 8.0, 10 mM EDTA, and 0.3% SDS) 
at 65°C for 50 min and purified using phenol-chloroform.
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The purified mononucleosomal DNA fragments by MNase 
digestion and the ChIP’ed DNA fragments on the nucleosomes 
with HMs by HM antibodies were subjected to massively parallel 
DNA sequencing on Illumina HiSeq2000 platform using 125-bp 
pair-end protocol, respectively.
RNA-Seq Data Analysis
RNA-seq reads were mapped to hg19 genome assembly and 
transcriptome by Hisat2 (Kim et al., 2015). Read counts of RefSeq 
annotated genes were calculated using featureCounts (Liao et al., 
2014). The read count matrix was input into DESeq2 (Love et 
al., 2014) to model the reads distribution and then the unwanted 
variations of the data were removed by RUVSeq package (Risso 
et al., 2014). The expression values of known RefSeq genes were 
calculated as Reads Per Kilobase per Million mapped reads (RPKM) 
using the normalized read counts of RUVSeq (Risso et al., 2014).
Gene expression signal tracks for the control and MYCN 
knockdown samples were generated from RNA-seq alignments 
of combined biological replicates using Deeptools2 (Ramirez et 
al., 2016) in 10-bp bins. The signals were normalized as RPKM.
Chip-Seq and MNase-Seq Data Analysis
Raw reads of ChIP-seq and MNase-seq data were trimmed for 
adapter sequences and low-quality bases using Trim Galore 
software. Then, the clean reads were mapped to hg19 genome 
assembly by Bowtie2 (Langmead and Salzberg, 2012), and only 
the proper pairs with high mapping quality (mapq > 10) were 
retained for further analysis. PCR duplicates were removed with 
Samtools (Li et al., 2009).
Genome-wide comparisons of biological replicates were 
processed as follows: First, the genome was divided into non-
overlapping 10-kb bins. Second, the read pairs’ midpoints were 
assigned to the bins for each biological replicate. Third, read 
count of each bin was calculated and normalized as RPKM. Then, 
the Pearson correlation coefficients between biological replicate 
pairs were calculated to measure the reproducibility of biological 
replicates.
As the reproducibility of biological replicates was high in 
ChIP-seq and MNase-seq, we pooled the biological replicates of 
each sample in further analysis.
We generated signal tracks of ChIP-seq and MNase-seq data 
using Deeptools2 (Ramirez et al., 2016) in 10-bp bins. The signals 
were normalized as RPKM.
Nucleosome Prediction and Positioning 
Dynamics Upon MYCN Knockdown
The midpoint position of proper read pairs of MNase-seq data 
was used as nucleosome dyad (termed as index) coordinate. Then, 
we used Genetrack (Albert et al., 2008) software to predict the 
nucleosome positions and calculate occupancy (the normalized 
read count) and fuzziness of each nucleosome from the index 
coordinate distributions. The fuzziness value was defined as the 
standard deviation of index coordinate’s distances to the predicted 
nucleosome dyad. The predicted nucleosomes with low read 
count (rc < 6) were filtered out to reduce false discovery rates.
The nucleosome positioning dynamics upon MYCN knockdown 
was analyzed as previous studies (Ye et al., 2016; Ye et  al., 2017) 
with minor modifications. The two closest nucleosomes in the 
control and MYCN knockdown samples were retained nucleosome 
pairs. For each nucleosome pair, the nucleosomes whose locations 
were not changed were defined as the fixed nucleosomes. The 
nucleosomes were shifted if their midpoint distance was ≥1 bp and 
<117 bp; that is, the two nucleosomes overlapped ≥30 bp and <147 
bp (a nucleosome length). The rest of the nucleosomes were gained 
or lost upon MYCN knockdown.
According to the composite distribution of nucleosomes relative 
to the TSS, the upstream 200-bp to downstream 50-bp regions of 
TSSs were the canonical nucleosome-free regions (NFRs). If an NFR 
in the control sample overlapped at least 80% of a nucleosome upon 
MYCN knockdown, the NFR was lost in the MYCN knockdown 
sample. Opposite to this, the NFR formed upon MYCN knockdown. 
We plotted nucleosome occupancy in the regions around these two 
sets of NFRs as heat maps and clustered it by K-means (K = 5).
Chromatin States of Genome Regions 
Determined by Histone Modifications
Chromatin states were identified and characterized by ChromHMM 
v1.15 (Ernst and Kellis, 2012) with distinct histone modification 
combinations. The genome was divided into 200-bp bins. We 
used BinarizedBam command to calculate H3K9ac, H3K4me3, 
H3K27me3, and H3K27ac signals with IgG samples as input for 
each bin, respectively. Then, the chromatin states were trained and 
learned from these bins with four emission states (two individual 
histone modifications, one combined histone modifications, none) 
in each of these three histone modification combinations (H3K9ac 
with H327me3, H3K4me3 with H3K27me3, and H3K27ac with 
H3K27me3). Finally, we got segments with four chromatin states 
genome-wide for each histone modification combination.
Chromatin State Changes in the 
Promoters Upon MYCN Knockdown
Promoters were defined as the upstream 2-kb regions to the 
downstream 1-kb regions of TSS. We took genomic segments 
classified by ChromHMM to define the chromatin states of 
promoters. The promoters that contain an H3K9ac+/H3K27me3+ 
segment, or both H3K9ac+ only segments and H3K27me3+ only 
segments were defined as H3K9ac+/H3K27me3+ promoters. The 
promoters that exclusively contain an H3K9ac+ only segments 
or H3K27me3+ only segments were defined as H3K9ac+ or 
H3K27me3+ promoters, respectively. The rest of the promoters 
were defined as no marked promoters. The chromatin states in 
the promoters for the combination of H3K4me3 with H3K27me3 
were classified in the same way.
Enhancer Predictions and 
Characterization
H3K4me1 peaks were identified using findPeaks command from 
Homer (Heinz et al., 2010) with the following parameter setting: 
-style histone -F 2. Peaks located within 2-kb regions of known 
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TSSs were excluded to avoid overlap with the promoters. For two 
peaks from the two samples that overlapped at least 50% of the 
shorter peak, the peak with higher Homer score was retained. The 
non-overlapping peaks were all retained as well. Peaks in ctrl and 
MYCN KD were merged using the following strategy: Overlap 
peaks (at least 50% overlap) with higher peak score were left and 
pooled with non-overlap peaks in each sample. The final peak 
set retained in this manner was treated as enhancers for further 
analysis. Enhancers with H3K4me1 peak(s) were at “On” state. In 
contrast, enhancers without a H3K4me1 peak were at “Off ” state.
For the enhancers defined by the overlapping H3K4me1 peaks 
from the two samples, we examined the length of the original 
peaks in each sample: If the peak length in the MYCN knockdown 
sample was over 1.5-fold wider than that in the control sample, 
this enhancer became broader upon MYCN knockdown. 
Similarly, if the peak length in the MYCN knockdown sample 
was over 1.5-fold shorter than that in the control sample, this 
enhancer became shorter upon MYCN knockdown.
We took the ChromHMM segments classified by the 
combination of H3K27ac with H3K27me3 as above to define 
the chromatin states of the “On” enhancers. The enhancers 
that contain an H3K27ac+/H3K27me3+ segment, or both 
H3K27ac+ only segments and H3K27me3+ only segments had 
an intermediate state. The enhancers that exclusively contain an 
H3K27ac+ only segment had an active state. The enhancers that 
exclusively contain an H3K27me3+ only segment had a poised 
state. The rest of “On” enhancers had a primed state.
The nearest TSS within 50-kb regions of an enhancer was 
defined as the enhancer target gene. Thus, a gene may associate 
with several enhancers.
The ggalluvial package in R was used to show the chromatin state 
dynamics in the promoters and the enhancers with alluvial plots.
Analysis of MYCN Chip-Seq Data in BE(2)
C Cells
We downloaded the public MYCN ChIP-seq data in BE(2)C cells 
(Zeid et al., 2018) and mapped the reads to hg19 genome assembly. 
MYCN peaks were called using MACS2 v2.1.1.20160309 (Liu, 
2014) with default parameters. The promoters and the enhancers 
were classified as “MYCN-bound” if they contain at least one 
MYCN peak. The rest of the promoters and the enhancer were 
classified as “no MYCN-bound”.
Functional Annotations
The GO term analysis of the genes with loss or gain in NFR in 
the promoter regions after MYCN knockdown (Figures 2B and 
S2C), of the genes whose enhancers changed from active to 
non-active, of the genes with NFR loss in the enhancers upon 
MYCN knockdown, and of the genes whose enhancers became 
broader and remained active upon MYCN knockdown (Figures 
4C, D and Supplementary Figure 4D) was carried out using the 
tool DAVID v6.8 (Huang et al., 2009) (https://david.ncifcrf.org). 
The GO term analysis of the genes with H3K9ac+/H3K27me3− 
promoters that are replaced by H3K27me3+, H3K9ac+/
H3K27me3+, or none after MYCN knockdown (Figure 3C) was 
performed with clusterProfiler (Yu et al., 2012).
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